Technical Analysis for ANNX - Annexon, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Historical ANNX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | -1.27% | |
Oversold Stochastic | Weakness | -1.27% | |
Doji - Bullish? | Reversal | -7.92% | |
Wide Bands | Range Expansion | -7.92% | |
Oversold Stochastic | Weakness | -7.92% | |
Narrow Range Bar | Range Contraction | -8.73% | |
NR7 | Range Contraction | -8.73% | |
Stochastic Reached Oversold | Weakness | -8.73% | |
Inside Day | Range Contraction | -8.73% | |
Wide Bands | Range Expansion | -8.73% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 2 hours ago |
Down 2 % | about 2 hours ago |
Down 1% | about 4 hours ago |
Fell Below Previous Day's Low | about 4 hours ago |
60 Minute Opening Range Breakdown | about 5 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Annexon, Inc. Description
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Eye Immune System Monoclonal Antibody Antibody Ophthalmic Biomarker Degenerative Disease Autoimmunity Platform Technology Neurodegenerative Disorders Complement System Intravitreal Administration
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 38.01 |
52 Week Low | 15.33 |
Average Volume | 182,469 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 28.43 |
20-Day Moving Average | 28.11 |
10-Day Moving Average | 25.58 |
Average True Range | 2.42 |
ADX | 21.0 |
+DI | 13.63 |
-DI | 25.21 |
Chandelier Exit (Long, 3 ATRs ) | 28.72 |
Chandelier Exit (Short, 3 ATRs ) | 30.44 |
Upper Bollinger Band | 34.49 |
Lower Bollinger Band | 21.74 |
Percent B (%b) | 0.12 |
BandWidth | 45.37 |
MACD Line | -1.42 |
MACD Signal Line | -0.89 |
MACD Histogram | -0.5322 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.67 | ||||
Resistance 3 (R3) | 25.91 | 25.34 | 25.26 | ||
Resistance 2 (R2) | 25.34 | 24.73 | 25.22 | 25.13 | |
Resistance 1 (R1) | 24.30 | 24.35 | 24.02 | 24.06 | 24.99 |
Pivot Point | 23.73 | 23.73 | 23.59 | 23.61 | 23.73 |
Support 1 (S1) | 22.69 | 23.12 | 22.41 | 22.45 | 21.51 |
Support 2 (S2) | 22.12 | 22.74 | 22.00 | 21.37 | |
Support 3 (S3) | 21.08 | 22.12 | 21.24 | ||
Support 4 (S4) | 20.84 |